An international serum standard for application in assays to detect human complement activation products

Molecular Immunology

Volumn 56, Issue 3, 2013, Pages 232-239

  Bergseth, Grethe ^a   Ludviksen, Judith K ^a   Kirschfink, Michael ^b   Giclas, Patricia C ^c   Nilsson, Bo ^d   Mollnes, Tom E ^e,f  

^a Nordland Hospital Bodø   (Norway)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^d UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

^f UNIVERSITY OF TROMSØ   (Norway)

Author keywords

Activation products; Assay; Complement; Standard

Indexed keywords

COMPLEMENT; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C3D; COMPLEMENT COMPONENT C4A; COMPLEMENT COMPONENT C4B; COMPLEMENT COMPONENT C4D; COMPLEMENT COMPONENT C5A; COMPLEMENT MEMBRANE ATTACK COMPLEX; EDETIC ACID; IMMUNOGLOBULIN G; LECTIN; ZYMOSAN;

BLOOD DONOR; CALIBRATION; COMPLEMENT ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FREEZING; HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUALITY CONTROL; REVIEW; THAWING; TITRIMETRY;

ACTIVATION PRODUCTS; ASSAY; COMPLEMENT; STANDARD;

COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; REFERENCE STANDARDS;

EID: 84880791985     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2013.05.221     Document Type: Review

References (19)

1. Bourke B.E., Moss I.K., Maini R.N. Measurement of the complement C3 breakdown product C3d by rocket immunoelectrophoresis. J. Immunol. Methods 1982, 48:97-108.
2. Deppisch R., Schmitt V., Bommer J., Hansch G.M., Ritz E., Rauterberg E.W. Fluid phase generation of terminal complement complex as a novel index of bioincompatibility. Kidney Int. 1990, 37:696-706.
3. Fure H., Nielsen E.W., Hack C.E., Mollnes T.E. A neoepitope-based enzyme immunoassay for quantification of C1-inhibitor in complex with C1r and C1s. Scand. J. Immunol. 1997, 46:553-557.
4. Garred P., Mollnes T.E., Lea T. Quantification in enzyme-linked immunosorbent assay of a C3 neoepitope expressed on activated human complement factor C3. Scand. J. Immunol. 1988, 27:329-335.
5. Harboe M., Thorgersen E.B., Mollnes T.E. Advances in assay of complement function and activation. Adv. Drug Deliv. Rev. 2011, 63:976-987.
6. Huber-Lang M., Sarma J.V., Zetoune F.S., Rittirsch D., Neff T.A., McGuire S.R., Lambris J.D., Warner R.L., Flierl M.A., Hoesel L.M., Gebhard F., Younger J.G., Drouin S.M., Wetsel R.A., Ward P.A. Generation of C5a in the absence of C3: a new complement activation pathway. Nat. Med. 2006, 12:682-687.
7. Mollnes T.E. Early- and late-phase activation of complement evaluated by plasma levels of C3d,g and the terminal complement complex. Complement 1985, 2:156-164.
8. Mollnes T.E., Kirschfink M. Complement analysis in clinic and research. Adv. Exp. Med. Biol. 2006, 586:361-380.
9. Mollnes T.E., Lea T., Frøland S.S., Harboe M. Quantification of the terminal complement complex in human plasma by an enzyme-linked immunosorbent assay based on monoclonal antibodies against a neoantigen of the complex. Scand. J. Immunol. 1985, 22:197-202.
10. Mollnes T.E., Redl H., Hogasen K., Bengtsson A., Garred P., Speilberg L., Lea T., Oppermann M., Gotze O., Schlag G. Complement activation in septic baboons detected by neoepitope-specific assays for C3b/iC3b/C3c, C5a and the terminal C5b-9 complement complex (TCC). Clin. Exp. Immunol. 1993, 91:295-300.
11. Mollnes T.E., Brekke O.L., Fung M., Fure H., Christiansen D., Bergseth G., Videm V., Lappegard K.T., Kohl J., Lambris J.D. Essential role of the C5a receptor in E. coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood 2002, 100:1869-1877.
12. Mollnes T.E., Jokiranta T.S., Truedsson L., Nilsson B., Rodriguez de C.S., Kirschfink M. Complement analysis in the 21st century. Mol. Immunol. 2007, 44:3838-3849.
13. Nilsson B., Ekdahl K.N. Complement diagnostics: concepts, indications, and practical guidelines. Clin. Dev. Immunol. 2012, 2012:962702.
14. Oppermann M., Wurzner R. Modern determination of complement activation. Semin. Thromb. Hemost. 2010, 36:611-619.
15. Pfeifer P.H., Kawahara M.S., Hugli T.E. Possible mechanism for in vitro complement activation in blood and plasma samples: Futhan/EDTA controls in vitro complement activation. Clin. Chem. 1999, 45:1190-1199.
16. Vogt W., Hesse D. Oxidants generated by the myeloperoxidase halide system activate the fifth component of human complement, C5. Immunobiology 1994, 192:1-9.
17. Wagner J.L., Hugli T.E. Radioimmunoassay for anaphylatoxins: a sensitive method for determining complement activation products in biological fluids. Anal. Biochem. 1984, 136:75-88.
18. Wiggins R.C., Giclas P.C., Henson P.M. Chemotactic activity generated from the fifth component of complement by plasma kallikrein of the rabbit. J. Exp. Med. 1981, 153:1391-1404.
19. Wolbink G.J., Bollen J., Baars J.W., Tenberge R.J.M., Swaak A.J.G., Paardekooper J., Hack C.E. Application of a monoclonal antibody against a neoepitope on activated C4 in an ELISA for the quantification of complement activation via the classical pathway. J. Immunol. Methods 1993, 163:67-76.